DK2937358T3 - Fremgangsmåder til behandling af multipel sklerose under anvendelse af antisense-oligonukleotider - Google Patents
Fremgangsmåder til behandling af multipel sklerose under anvendelse af antisense-oligonukleotider Download PDFInfo
- Publication number
- DK2937358T3 DK2937358T3 DK15155831.9T DK15155831T DK2937358T3 DK 2937358 T3 DK2937358 T3 DK 2937358T3 DK 15155831 T DK15155831 T DK 15155831T DK 2937358 T3 DK2937358 T3 DK 2937358T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- multiple sclerosis
- antisense oligonucleotides
- treating multiple
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13297308P | 2008-06-23 | 2008-06-23 | |
| EP09798248.2A EP2318424B1 (en) | 2008-06-23 | 2009-06-23 | Methods for treating multiple sclerosis using antisense oligonucleotides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2937358T3 true DK2937358T3 (da) | 2019-01-02 |
Family
ID=41550900
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15155831.9T DK2937358T3 (da) | 2008-06-23 | 2009-06-23 | Fremgangsmåder til behandling af multipel sklerose under anvendelse af antisense-oligonukleotider |
| DK09798248T DK2318424T3 (en) | 2008-06-23 | 2009-06-23 | A method for the treatment of multiple sclerosis by the use of antisense oligonucleotides |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09798248T DK2318424T3 (en) | 2008-06-23 | 2009-06-23 | A method for the treatment of multiple sclerosis by the use of antisense oligonucleotides |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8415314B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2937358B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5988581B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009271678B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2728562C (cg-RX-API-DMAC7.html) |
| DK (2) | DK2937358T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2699891T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010008474A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8415314B2 (en) | 2008-06-23 | 2013-04-09 | Antisense Therapeutics Limited | Methods for treating multiple sclerosis using antisense oligonucleotides |
| WO2012034194A1 (en) * | 2010-09-17 | 2012-03-22 | Antisense Therapeutics Ltd | Method for mobilizing stem and/or progenitor cells |
| EP3294889B1 (en) * | 2015-05-11 | 2021-01-06 | Murdoch University | Multiple sclerosis treatment |
| US11891606B2 (en) * | 2017-06-16 | 2024-02-06 | Antisense Therapeutics Ltd | Methods for treating multiple sclerosis using antisense oligonucleotides |
| EP3787639A4 (en) * | 2018-05-04 | 2022-02-23 | Antisense Therapeutics Ltd | THERAPEUTIC USES AND PROCESSES |
| CA3138945A1 (en) * | 2019-05-06 | 2020-11-12 | Antisense Therapeutics Ltd | Methods for treating muscular dystrophy using inhibitory oligonucleotides to cd49d |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6242591B1 (en) * | 1997-10-15 | 2001-06-05 | Isis Pharmaceuticals, Inc. | Synthesis of sulfurized 2'-substituted oligonucleotides |
| US5968826A (en) * | 1998-10-05 | 1999-10-19 | Isis Pharmaceuticals Inc. | Antisense inhibition of integrin α4 expression |
| WO2005108610A2 (en) * | 2004-04-05 | 2005-11-17 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Methods for the selection of subjects for multiple sclerosis therapy |
| AU2005327506B2 (en) * | 2004-10-20 | 2010-07-08 | Antisense Therapeutics Ltd | Antisense modulation of integrin alpha4 expression |
| US8415314B2 (en) | 2008-06-23 | 2013-04-09 | Antisense Therapeutics Limited | Methods for treating multiple sclerosis using antisense oligonucleotides |
-
2009
- 2009-06-23 US US12/456,883 patent/US8415314B2/en not_active Expired - Fee Related
- 2009-06-23 EP EP15155831.9A patent/EP2937358B1/en active Active
- 2009-06-23 DK DK15155831.9T patent/DK2937358T3/da active
- 2009-06-23 JP JP2011516297A patent/JP5988581B2/ja not_active Expired - Fee Related
- 2009-06-23 CA CA2728562A patent/CA2728562C/en active Active
- 2009-06-23 EP EP09798248.2A patent/EP2318424B1/en not_active Not-in-force
- 2009-06-23 ES ES15155831T patent/ES2699891T3/es active Active
- 2009-06-23 DK DK09798248T patent/DK2318424T3/en active
- 2009-06-23 ES ES09798248.2T patent/ES2532404T3/es active Active
- 2009-06-23 WO PCT/US2009/003760 patent/WO2010008474A2/en not_active Ceased
- 2009-06-23 AU AU2009271678A patent/AU2009271678B2/en not_active Ceased
-
2013
- 2013-03-22 US US13/848,811 patent/US8759314B2/en active Active
-
2014
- 2014-10-09 JP JP2014208153A patent/JP6131230B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2937358B1 (en) | 2018-09-19 |
| JP5988581B2 (ja) | 2016-09-07 |
| JP6131230B2 (ja) | 2017-05-17 |
| WO2010008474A4 (en) | 2011-01-27 |
| ES2532404T3 (es) | 2015-03-26 |
| EP2318424A4 (en) | 2012-12-26 |
| EP2937358A1 (en) | 2015-10-28 |
| CA2728562C (en) | 2018-10-23 |
| WO2010008474A3 (en) | 2010-04-22 |
| EP2318424A2 (en) | 2011-05-11 |
| AU2009271678B2 (en) | 2013-09-19 |
| DK2318424T3 (en) | 2015-04-07 |
| CA2728562A1 (en) | 2010-01-21 |
| US20130345293A1 (en) | 2013-12-26 |
| EP2318424B1 (en) | 2015-02-25 |
| US8759314B2 (en) | 2014-06-24 |
| AU2009271678A1 (en) | 2010-01-21 |
| ES2699891T3 (es) | 2019-02-13 |
| US8415314B2 (en) | 2013-04-09 |
| JP2015044824A (ja) | 2015-03-12 |
| US20100119480A1 (en) | 2010-05-13 |
| JP2011525531A (ja) | 2011-09-22 |
| WO2010008474A2 (en) | 2010-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL232222A0 (en) | Methods for treating progressive multiple sclerosis | |
| EP2262892A4 (en) | EXPRESSION OF HETEROLOGOUS SEQUENCES | |
| DK2417257T3 (da) | Tricyclo-dna-antisense-oligonukleotider, sammensætninger, og fremgangsmåder til behandlingen af sygdom | |
| DK2293816T3 (da) | Fremgangsmåder til behandling af reumatoid arthritis | |
| DK2498771T3 (da) | Anvendelse af bethanechol til behandling af xerostomi | |
| EP2310144A4 (en) | COATINGS | |
| DK2448637T3 (da) | Anvendelse af ét fytocannabinoid eller en kombination af fytocannabinoider til behandling af epilepsi | |
| BRPI0910259A2 (pt) | métodos de tratamento de inflamação | |
| DK3517534T3 (da) | Forbindelser, der er anvendelige til behandling af cancer | |
| BRPI0917575A2 (pt) | métodos de tratamento de talassemia | |
| BRPI0910854A2 (pt) | métodos de tratamento | |
| DK3121280T3 (da) | Antisense-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf | |
| BRPI0921482A2 (pt) | tratamento de leucemia linfoblástica aguda | |
| HRP20180718T1 (hr) | Oligopeptidni spojevi i njihova upotreba | |
| DK2350116T3 (da) | Behandling af biofilm | |
| EP2132315A4 (en) | REOVIRUS HAVING MODIFIED SEQUENCES | |
| BRPI0919127A2 (pt) | métodos para tratamento de água | |
| PL2205720T3 (pl) | Kompozycja do leczenia stwardnienia rozsianego | |
| DK2382232T3 (da) | Fremgangsmåde til fremstilling af bivalirudin | |
| DK2164572T3 (da) | Carbamoyl-cyclohexaner til behandling af akut mani | |
| BRPI0920224A2 (pt) | inibição de plgf para tratar leucemia positiva para cromossoma filadélfia | |
| DK2131841T3 (da) | Fremgangsmåder til behandling af akut smerte | |
| DK2937358T3 (da) | Fremgangsmåder til behandling af multipel sklerose under anvendelse af antisense-oligonukleotider | |
| BRPI0822129A2 (pt) | Inibidores de aldh-2c no tratamento de vício. | |
| DE112009002122A5 (de) | Beschichtungsverfahren |